{"id":296386,"date":"2026-05-08T00:00:00","date_gmt":"2026-05-08T00:00:00","guid":{"rendered":"https:\/\/clarivate.com\/life-sciences-healthcare\/report\/cutrcg0001-2024-biopharma-alzheimers-disease-current-treatment-current-treatment-physician-insights\/"},"modified":"2026-06-19T11:09:18","modified_gmt":"2026-06-19T11:09:18","slug":"cutrcg0001-2026-biopharma-alzheimers-disease-current-treatment-current-treatment-physician-insights-alzheimers","status":"publish","type":"report","link":"https:\/\/clarivate.com\/life-sciences-healthcare\/report\/cutrcg0001-2026-biopharma-alzheimers-disease-current-treatment-current-treatment-physician-insights-alzheimers\/","title":{"rendered":"Alzheimer&#8217;s Disease &#8211; Current Treatment &#8211; Current Treatment: Physician Insights &#8211; Alzheimer&#8217;s Disease (US)"},"content":{"rendered":"<p>Alzheimer\u2019s disease (<abbr title=\"Alzheimer's disease\">AD<\/abbr>) affects cognition and causes neuropsychiatric symptoms (e.g., agitation, aggression, psychosis) that intensify as the disease advances. Disease-modifying therapy (<abbr title=\"disease-modifying therapy\">DMT<\/abbr>) is now a reality in <abbr title=\"Alzheimer's disease\">AD<\/abbr> with the availability of Eisai \/ Biogen\u2019s Leqembi \/ Leqembi Iqlik (lecanemab) and Eli Lilly\u2019s Kisunla (donanemab). These agents are vying for uptake and beginning to unlock the potential of a <abbr title=\"disease-modifying therapy\">DMT<\/abbr> as the U.S. healthcare system adapts to identify <abbr title=\"Alzheimer's disease\">AD<\/abbr> patients earlier in the disease course. Lundbeck \/ Otsuka\u2019s Rexulti (brexpiprazole) is the first drug <abbr title=\"Food and Drug Administration\">FDA<\/abbr>-approved for <abbr title=\"Alzheimer's disease\">AD<\/abbr> agitation, and the late-phase pipeline holds numerous additional competitors. This report will provide developers of new and emerging <abbr title=\"disease-modifying therapy\">DMT<\/abbr>s and neuropsychiatric treatments for <abbr title=\"Alzheimer's disease\">AD<\/abbr> with insights into the patient characteristics driving or constraining eligibility for novel options. It will also delve into diagnosis and treatment initiation in <abbr title=\"Alzheimer's disease\">AD<\/abbr>, as well as neurologists\u2019 and <abbr title=\"primary care physician\">PCP<\/abbr>s\u2019 prescribing practices and rationale. prescribing practices and rationale.<\/p>\n<p><strong>Questions answered<\/strong><\/p>\n<ul class=\"round-bullets\">\n<li>What factors are driving the selection between Leqembi and Kisunla? What are key drivers and constrainers of their use?<\/li>\n<li>What percentage of <abbr title=\"Alzheimer's disease\">AD<\/abbr> patients have comorbid behavioral conditions? What do neurologists prescribe to treat these symptoms?<\/li>\n<li>How have neurologists\u2019 and <abbr title=\"primary care physician\">PCP<\/abbr>s\u2019 prescribing changed in the past year? What changes are they anticipating in the coming year?<\/li>\n<li>How do <abbr title=\"primary care physician\">PCP<\/abbr>s and neurologists differ in their prescribing practices?<\/li>\n<li>What types of assessments are physicians completing at follow-up appointments after initiating Leqembi?<\/li>\n<li>Which biomarker tests are clinicians using, and how?<\/li>\n<li>What percentage of <abbr title=\"Alzheimer's disease\">AD<\/abbr> patients are on antipsychotics, and what is the patient share of individual therapies?<\/li>\n<\/ul>\n<p><strong>Product description<\/strong><\/p>\n<p>Current Treatment: Physician Insights provides physician insights on treatment dynamics, prescribing behavior, and drivers of brand use so that marketers can create specific messaging around these treatment dynamics to more effectively increase or defend their market position.<\/p>\n<p><strong>Markets covered: <\/strong>United States<\/p>\n<p><strong>Primary research: <\/strong>Survey of 70 U.S. neurologists and 30 U.S. <abbr title=\"primary care physician\">PCP<\/abbr>s<\/p>\n<p><strong>Key drugs covered: <\/strong>Leqembi\u00a0\/ Leqembi Iqlik, Kisunla,\u00a0Rexulti, donepezil, galantamine, memantine, Namzaric, rivastigmine, atypical antipsychotics, antidepressants<\/p>\n<p><strong>Key companies: <\/strong>Eisai \/ Biogen, Otsuka \/ Lundbeck, AbbVie, Eli Lilly<\/p>\n<p><strong>Key insights provided: <\/strong><\/p>\n<ul class=\"round-bullets\">\n<li>Factors influencing disease management and treatment decisions.<\/li>\n<li>Drivers and constraints of treatment selection.<\/li>\n<li>Physician-reported treatment practices and brand-level patient shares.<\/li>\n<li>Rationale for changes in treatment approach.<\/li>\n<li>Physician insight on persistency and compliance.<\/li>\n<li>Physician-reported recent\/anticipated changes in brand usage or treatment approach.<\/li>\n<\/ul>\n","protected":false},"template":"","class_list":["post-296386","report","type-report","status-publish","hentry","report-gateway-biopharma","biopharma-therapy-areas-alzheimers-disease","biopharma-therapy-areas-neurology","biopharma-product-current-treatment","biopharma-geography-us","biopharma-date-2609"],"acf":[],"publishpress_future_workflow_manual_trigger":{"enabledWorkflows":[]},"_links":{"self":[{"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/report\/296386","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/report"}],"about":[{"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/types\/report"}],"wp:attachment":[{"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/media?parent=296386"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}